**CERo Therapeutics Holdings, Inc. Reports Financial Results in Form 10-K Filing**
CERo Therapeutics Holdings, Inc., a clinical-stage immunotherapy company, released its Form 10-K filing, detailing its financial performance and operational activities for the fiscal year ended December 31, 2025. The company reported a net loss of $19.9 million for the year, a significant increase from the $8.3 million net loss reported for the pro forma year ended December 31, 2024. Research and development expenses increased to $10.4 million in 2025, up from $7.1 million in the previous year, reflecting the company's focus on advancing its lead product candidate, CER-1236, through clinical trials. General and administrative expenses decreased to $8.1 million from $9.1 million in the prior year, primarily due to a decrease in expenses related to the business combination.
The company's financial position as of December 31, 2025, showed cash and cash equivalents of $1.7 million, a decrease from $3.3 million at the end of 2024. The company's accumulated deficit increased to $90.8 million. Net cash used in operating activities was $16.1 million for 2025, compared to $12.9 million for the pro forma year ended December 31, 2024. The company has identified material weaknesses in its internal control over financial reporting, which it is actively working to remediate.
Operationally, CERo Therapeutics initiated a Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML) in May 2025 and submitted a second IND application for CER-T cell therapy in non-small cell lung cancer (NSCLC) and ovarian cancer, which was accepted by the FDA in March 2025. The company also received FDA Orphan Drug Designation and Fast Track Designation for CER-1236 in AML. However, Nasdaq delisted the company's securities in October 2025, and trading commenced on the OTCQB market in December 2025.
Looking ahead, CERo Therapeutics anticipates initiating a Phase 1 study in NSCLC and ovarian cancer in the first quarter of 2026. The company expects to continue incurring significant expenses as it advances its clinical development programs and builds its manufacturing infrastructure. Management has expressed substantial doubt about the company's ability to continue as a going concern, highlighting the need for additional financing to support its operations. The company is actively seeking additional funding through various means, including equity lines of credit and private placements.
About CERO THERAPEUTICS HOLDINGS, INC.
Cero Therapeutics develops innovative engineered T cell therapies for cancer, focusing on both hematological malignancies and solid tumors. Its platform integrates innate and adaptive immune functions into CER-T cells, targeting tumor-specific antigens like TIM-4-L. The company's lead candidate, CER-1236, aims to enhance tumor clearance via cytotoxic, phagocytic, and antigen presentation mechanisms, leveraging well-established CAR-T manufacturing processes for broad cancer treatment applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.